This map demonstrates the breadth of HIV prevention research and demonstration projects in the Kisumu region of Kenya by site and type (e.g. daily oral PrEP, preventive Vaccines, etc.). This map was developed by Wits RHI with support from AVAC as part of the Coalition to Accelerate and Support Prevention Research.
Map of HIV Prevention Research and PrEP Demonstration Sites in Kisumu, Kenya
Oral PrEP Uptake in South Africa: A snapshot from mid-2017
This graphic provides a closer look at PrEP uptake at several sites in South Africa along with lessons learned. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
Timeline for DAIDS HIV Trials Network Recompetition
This graphic looks ahead from 2017 through 2027 at the DAIDS HIV Trials Network Recompetition process. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
The UNAIDS 10-Point Plan for Making Progress on Prevention
The UNAIDS 10-point plan for making progress on prevention omits elements of the “research-to-rollout” continuum, and leaves the definition of prevention out—focusing on the “how” rather than the “what”. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
Driving Product Introduction and Access
AVAC has always advocated for closing critical prevention gaps. Now we’re taking our mission further. With African and global partners, we’re stepping beyond advocacy to generate the knowledge and tools that countries need to more quickly deliver new advances.
We’re engaging directly with national decision-makers to identify and overcome delivery hurdles for PrEP. We’re examining the preferences and experiences of people at high risk for HIV, so that future tools—long-acting injectables, vaginal rings and others—can be optimized to meet their needs.
South African HIV Prevention Research and Demonstration Sites
South Africa’s Trial Sites: An overview of HIV prevention research and demonstration sites in 2017, by location and intervention.
From Proof-of-Concept to Prevention Phenomenon in Five Years
This timeline, first appearing in AVAC Report 2014/15: HIV Prevention on the Line, shows PrEP going from proof-of-concept to prevention phenomenon in five years and can be used to anticipate and speed action on the next generation of ARV-based prevention options.
HIV-Specific Neutralizing Antibodies: A guide to targets and candidates
A detailed graphic describing the status of pre-clinical and clinical work around relevant bNAbs today.
Where Does Oral PrEP Fit in to Vaccine and AMP Trials?
A global map showing current efficacy trial countries and their status of PrEP implementation.
Vaccine Approaches in Early-Phase Development
An outline of various approaches to vaccine development that are in earlier phase research, e.g., phase I or II trials; development pathways for these candidates are uncertain at this time.